Affymetrix receives clearance to market CytoScan Dx Assay Affymetrix announced that it has received 510k clearance from the FDA to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children’s developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.
News For AFFX From The Last 14 Days
Check below for free stories on AFFX the last two weeks.